- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
- Tumor immunotherapy evaluation — Study IDO1-mediated tryptophan metabolism in tumor immune escape; evaluate IDO1 inhibitors and IDO1-targeted agents, alone or combined with immune checkpoint inhibitors (anti-PD-1/PD-L1).
- Autoimmune & inflammatory disease — Investigate IDO1 in T cell regulation, immune tolerance induction, and suppression of autoimmune responses; establish IDO1-deficiency models of autoimmune disease and chronic inflammation.
- Metabolism & immune microenvironment — Assess how IDO1-derived tryptophan metabolites (e.g., kynurenine) shape the tumor microenvironment and immune cell function.
This mouse strain is generated through gene editing technology to specifically knock out the indoleamine 2,3-dioxygenase 1 (IDO1) gene. IDO1 is a rate-limiting enzyme that catalyzes the metabolism of tryptophan along the kynurenine pathway. It is highly expressed in tumor cells, antigen-presenting cells, and certain inflammatory environments. By depleting tryptophan and producing metabolites in the microenvironment, it suppresses effector T cell function and promotes regulatory T cell generation, thereby inducing immune tolerance and facilitating tumor immune escape. This model provides a key tool for in vivo studies on the function of IDO1 in tumor immunity, autoimmunity, pregnancy immune tolerance, and infection immunity. It is particularly suitable for pharmacodynamic evaluation of IDO1-targeted drugs and the development of combination therapy strategies.
- Complete enzymatic knockout — L-tryptophan 2,3-dioxygenase activity is eliminated, removing the rate-limiting step of the kynurenine pathway rather than merely inhibiting it pharmacologically.
- Downstream pathway ablation — Kynurenic acid and quinolinate biosynthesis are lost (NCBI mutant-phenotype evidence), giving clean downstream metabolite readouts.
- Defined T cell tolerance endpoints — NCBI-annotated negative regulation of T cell and activated T cell proliferation, plus positive regulation of T cell tolerance induction, support mechanistic tolerance studies.
- Clean background for IDO1-targeted drug testing — No endogenous IDO1 to confound inhibitor pharmacology or combination regimens with checkpoint blockade.
- Beyond oncology — The same strain supports pre-eclampsia (NCBI-annotated study use), chronic inflammation, and infection immunity work; IDO ablation also derepresses type I IFN and restricts retroviral replication in vivo.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.

